Drug Trial Radar · NCT07019675
A Study of SKB518 in Patients With Lung Cancer
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Aug 29, 2025
Primary completion
Feb 20, 2027
Study completion Oct 20, 2027
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Conditions
- Lung Carcinoma
Interventions
SKB518Drug
SKB518 is administered every 3 weeks(Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
TislelizumabDrug
Tislelizumab is administered every 3 weeks(200 mg, Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
CarboplatinDrug
Carboplatin is administered at every 3 weeks(AUC 5 mg/mL/min, Q3W) for 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- AETime frame: Up to 24 months
- ORR in specific armsTime frame: Up to 24 months
- PFS in specific armTime frame: Up to 24 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Science
Beijing, China · Recruiting
Shanghai Pulmonary Hospital (Affiliated to Tongji University)
Shanghai, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China · Recruiting
Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.